Đang chuẩn bị liên kết để tải về tài liệu:
Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: A single-institute analysis
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. |